Abstract:Background Masked hypertension is associated with target organ damage (TOD) and adverse health outcomes, but whether antihypertensive treatment improves TOD in patients with masked hypertension is unproven. Methods In this multicentre, randomised, double-blind, placebo-controlled trial at 15 Chinese hospitals, untreated outpatients aged 30-70 - 70 years with an office fi ce blood pressure (BP) of <140/<90 mm Hg and 24-h, daytime or nighttime ambulatory BP of >= 130/ >= 80, >= 135/ >= 85, or >= 120/ >= 70 mm Hg were enrolled. Patients had >= 1 sign of TOD: electrocardiographic left ventricular hypertrophy (LVH), brachial-ankle pulse wave velocity (baPWV) >= 1400 cm/s, or urinary albumin-to-creatinine ratio (ACR) >= 3.5 mg/mmol in women and >= 2.5 mg/mmol in men. Exclusion criteria included secondary hypertension, diabetic nephropathy, serum creatinine >= 176.8 mu mol/L, and cardiovascular disease within 6 months of screening. After stratification fi cation for centre, sex and the presence of nighttime hypertension, eligible patients were randomly assigned (1:1) to receive antihypertensive treatment or placebo. Patients and investigators were masked to group assignment. Active treatment consisted of allisartan starting at 80 mg/day, to be increased to 160 mg/day at month 2, and to be combined with amlodipine 2.5 mg/ day at month 4, if the ambulatory BP remained uncontrolled. Matching placebos were used likewise in the control group. The primary endpoint was the improvement of TOD, defined fi ned as normalisation of baPWV, ACR or LVH or a >= 20% reduction in baPWV or ACR over the 48-week follow-up. The intention-to-treat analysis included all randomised patients, the per-protocol analysis patients who fully adhered to the protocol, and the safety analysis all patients who received at least one dose of the study medication. This study is registered with ClinicalTrials.gov, NCT02893358. Findings Between February 14, 2017, and October 31, 2020, 320 patients (43.1% women; mean age +/- SD 53.7 +/- 9.7 years) were enrolled. Baseline office fi ce and 24-h BP averaged 130 +/- 6.0/81 +/- 5.9 mm Hg and 136 +/- 8.6/84 +/- 6.1 mm Hg, and the prevalence of elevated baPWV, ACR and LVH were 97.5%, 12.5%, and 7.8%, respectively. The 24-h BP decreased on average (+/- SE) by 10.1 +/- 0.9/6.4 +/- 0.5 mm Hg in 153 patients on active treatment and by 1.3 +/- 0.9/1.0 +/- 0.5 mm Hg in 167 patients on placebo. Improvement of TOD occurred in 79 patients randomised to active treatment and in 49 patients on placebo: 51.6% (95% CI 43.7%, 59.5%) versus 29.3% (22.1, 36.5%; p < 0.0001). Per-protocol and subgroup analyses were confirmatory. fi rmatory. Adverse events were generally mild and occurred in 38 (25.3%) and 43 (26.4%) patients randomised to active treatment and placebo, respectively (p = 0.83). Interpretation Our results suggest that antihypertensive treatment improves TOD in patients with masked hypertension, highlighting the need of treatment. However, the long-term benefit fi t in preventing cardiovascular complications still needs to be established.

Persistence of Masked Hypertension in Chinese Patients.

SUBTYPES OF MASKED HYPERTENSION AND THEIR ASSOCIATIONS WITH TARGET ORGAN DAMAGE IN UNTREATED CHINESE PATIENTS

Subtypes of masked hypertension and target organ damage in untreated outpatients

ANTIHYPERTENSIVE TREATMENT OF MASKED HYPERTENSION GUIDED BY AMBULATORY BLOOD PRESSURE MONITORING: A DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

Prevalence And Characteristics Of Exaggerated Morning Surge And Morning Hypertension In Chinese Patients: China Ambulatory And Home Blood Pressure Registry (Abpr)

ANTIHYPERTENSIVE TREATMENT IN MASKED HYPERTENSION FOR TARGET ORGAN PROTECTION (ANTI-MASK): A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL

A0241 Use of Ambulatory Blood Pressure Monitoring in the Diagnosis of White Coat and Masked Hypertension

The prevalence of masked hypertension and masked uncontrolled hypertension in relation to overweight and obesity in a nationwide registry in China

Treatment of Masked Hypertension with a Chinese Herbal Formula: A Randomized, Placebo-Controlled Trial

Treatment of masked hypertension with a chinese herbal formula: a randomized, placebo-controlled, single-blind trial

The prevalence of masked hypertension in relation to cigarette smoking in a Chinese male population

Utility of 24-hour ambulatory blood pressure monitoring for detecting masked hypertension and masked uncontrolled hypertension

Hypertension in China: the Gap Between Policy and Practice

Association of Cardiovascular Outcomes With Masked Hypertension Defined by Home Blood Pressure Monitoring in a Japanese General Practice Population

A Comparative Meta-Analysis of Prospective Observational Studies on Masked Hypertension and Masked Uncontrolled Hypertension Defined by Ambulatory and Home Blood Pressure

Efficacy of Antihypertensive Treatment for Target Organ Protection in Patients with Masked Hypertension (ANTI-MASK): a Multicentre, Double-Blind, Placebo-Controlled Trial

Prevalence of Masked Hypertension among US Adults with Nonelevated Clinic Blood Pressure.

Using Latent Class Analysis to Identify Different Risk Patterns for Patients With Masked Hypertension

Accuracy of Home Versus Ambulatory Blood Pressure Monitoring in the Diagnosis of White-Coat and Masked Hypertension

Masked hypertension is “unmasked” by low-intensity exercise blood pressure

Setting Thresholds to Varying Blood Pressure Monitoring Intervals Differentially Affects Risk Estimates Associated with White-Coat and Masked Hypertension in the Population.